CD10、SMA和P63在乳腺肌上皮细胞中的表达差异及意义

The expression and significance of CD10, SMA and P63 on human breast myoepithelial cells

目的研究普通急性淋巴母细胞性白血病抗原（CD10）、平滑肌肌动蛋白（SMA）、P63在乳腺良恶性病变肌上皮细胞中的表达差异及其临床意义。方法采用sP免疫组化方法检测CD10、SMA、P63在68例乳腺良恶性病变（乳腺纤维腺瘤或纤维腺病、上皮非典型增生、原位癌和浸润癌）肌上皮细胞中的表达情况。结果在乳腺增生病变（10例乳腺纤维腺瘤和纤维腺病及13例乳腺导管上皮轻、中及重度非典型增生病例）中，三种抗体均显示病变导管周围肌上皮层完整阳性，呈花环状结构，染色强度均为2＋-3＋；在15例乳腺导管原位癌病例中，显示肌上皮细胞层3＋完整阳性的导管数／病变导管总数的结果分别是：CD10抗体为92／384（23．96％）、SMA抗体为185／384（48．18％）、P63为80／384（20．83％）。三种抗体在肌上皮细胞中表达的阳性率有差别（P〈0．05）。另外，SMA抗体染色有6／15（40％）病例显示所有导管肌上皮层2＋／3＋完整阳性，CD10和P63抗体各为4／15（26．7％）病例阳性。抗体表达阴性率分别为CD10：170／384（44．27％），SMA：74／384（19．27％）、P63：127／384（33．07％）；在30例乳腺浸润癌（浸润性导管癌和浸润性小叶癌）中，三种抗体染色肌上皮细胞均显示阴性结果。结论CD10可成为继SMA，P63后又一个肌上皮细胞标记抗体，对判断乳腺疾病中肌上皮细胞存在与否提供依据。

Objective To study the expression and significance of CD10, SMA, P63 on human breast myoepithelial cells. Methods SP immunohistochemieal method was used to examine the expression of CD10, SMA, P63 on human breast myoepithelial ceils from 68 breast diseases samples, including breast fibroadenoma, breast fibroadenosis, breast atypical ductal hyperplasias, ductal carcinomas in situ and breast invasive carcinomas. Results 2 ＋/3 ＋ circumferential CD10, SMA and P63 staining of MEC was seen in I0 patients with breast fibroadenoma, breast fibroadenoma and 13 patients with atypical ductal hyperplasias. In an analysis of total ducts by 15 patients with breast duetal carcinomas in situ, 3 ＋ cireumfenrential staining was seen in 92 of 384 ducts（23.96% ） stained for CD10 versus 185 of 384 ducts （48.18%） stained for SMA and 80 of 384 ducts（20. 83% ） stained for P63. All differences among percentage positively stained of these three antibodies was significant, p-values was lower 0.05. MECs were not found with immunohistochemistry in 170 of 384 ducts （44. 27% ） with anti-CD10,74 of 384 ducts（ 19. 27% ）with anti-SMA and 127 of 384 ducts（33.07% ） with anti-P63. MECs were not found with CD10, SMA and P63 in 30 patients with breast invasive carcinomas. Conclusion We concluded that CD10 could be another useful marker of breast myoepithelial cells after SMA and P63. It provided more sophisticated information about presence or absence of breast myoepithelial ceils in confusing breast lesions.